课题基金 / 基金详情

BREAST CANCER AND BONE METASTASIS

BREAST CANCER AND BONE METASTASIS
乳腺癌和骨转移
批准号:
2856368
负责人:
TOSHIYUKI YONEDA
金额:
$16.91万
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-03-10 至 2000-12-31

项目摘要

项目成果

TOSHIYUKI YONEDA的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(改编自研究者摘要)一些实体瘤
英文摘要
DESCRIPTION: (Adapted From Investigator's Abstract) Some solid tumors such as breast cancer have a special predilection to cause osteolytic metastases. The investigators have developed an in vivo model to study the capacity of human breast cancer cells to form osteolytic bone lesions in vivo using a modification of a technique developed by others to study mechanisms of bone metastasis by animal tumors. Human breast cancer cells are inoculated into the left ventricle of the heart of nude mice, and osteolytic bone lesions are then assessed during the following 4 weeks in the vertebrae and extremities by x-ray and quantitative histology. The applicants plan to use this model to characterize the properties of human breast cancer cells which are responsible for bone metastasis and osteolytic bone destruction. In particular, they plan to study specific properties of cultured human breast cancer cells which may be related to metastasis to bone and osteolysis, including expression of cell attachment proteins which bind to laminin, to E-cadherin and the production of proteolytic enzymes or their inhibitors. They also plan to use this model to examine potential therapeutic approaches to prevent or inhibit the development of osteolytic bone lesions. With this model, they will select subpopulations of cells with enhanced capacity to cause osteolytic bone destruction, investigate the role of cell attachment proteins such as laminin and E-cadherin by the use of specific antagonists, antibodies and transfected cells, and the role of matrix metalloproteases and their inhibitors in osteolysis caused by human breast cancer cells in this model. The overall goal is to identify some of these molecular mechanisms which are responsible for osteolysis in vivo, so that rational therapeutic approaches can be devised to prevent or reverse bone destruction associated with metastatic breast cancer.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
双膦酸盐伊班膦酸盐和基质金属蛋白酶-2组织抑制剂联合治疗抑制乳腺癌溶骨性骨转移。
DOI: 10.1172/jci119435
发表时间: 1997
期刊: The Journal of clinical investigation
影响因子: --
作者: [Yoneda,T, Sasaki,A, Dunstan,C, Williams,PJ, Bauss,F, DeClerck,YA, Mundy,GR]
通讯作者: Mundy,GR
DOI: 10.1016/s0959-8049(97)10132-0
发表时间: 1998-02
期刊: European journal of cancer
影响因子: 8.4
作者: [T. Yoneda]
通讯作者: T. Yoneda
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
p53 蛋白的积累在与 BRCA1 和 BRCA2 种系突变相关的卵巢癌中很常见。
DOI: 10.1136/jcp.52.5.372
发表时间: 1999
期刊: Journal of clinical pathology
影响因子: 3.4
作者: [Zweemer,RP, Shaw,PA, Verheijen,RM, Ryan,A, Berchuck,A, Ponder,BA, Risch,H, McLaughlin,JR, Narod,SA, Menko,FH, Kenemans,P, Jacobs,IJ]
通讯作者: Jacobs,IJ
E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
在实验性转移模型中,人乳腺癌细胞中 E-钙粘蛋白的表达可抑制溶骨性骨转移的发展。
DOI: --
发表时间: 1996
期刊: Cancer research.
影响因子: --
作者: [Mbalaviele,G, Dunstan,CR, Sasaki,A, Williams,PJ, Mundy,GR, Yoneda,T]
通讯作者: Yoneda,T
Osteopontin and Bone Metastasis in Breast Cancer
Osteopontin and Bone Metastasis in Breast Cancer
Osteopontin and Bone Metastasis in Breast Cancer
Osteopontin and Bone Metastasis in Breast Cancer
海外基金